Background: Many studies have explored the prognostic value of T-cell lymphoma invasion and metastasis inducing factor 1 (Tiam1) and its association with lymphatic metastasis in malignant solid tumors, but the conclusions remain controversial. Therefore, we performed a meta-analysis to systematically assess the prognostic value of Tiam1 expression and its association with lymphatic metastasis in malignant solid tumors. Methods: We searched eligible studies in PubMed, Web of Science and EMBASE databases (from inception up to October 2018). The combined HR with 95% CI was used to estimate the prognostic value of Tiam1 expression. The correlation between Tiam1 expression and lymphatic metastasis was assessed using the combined odds ratio (OR) with 95% CI. Results: A total of 17 studies with 2,228 patients with solid tumors were included in this meta-analysis. The overall estimated results showed that high Tiam1 expression was significantly associated with shorter overall survival (HR= 2.08, 95% CI: 1.62-2.68, P<0.01), and disease-free survival (HR = 1.86, 95% CI: 1.49-2.32, P<0.01). Besides, we also found that there was a close relationship between high Tiam1 expression and positive lymphatic metastasis (OR=2.63; 95% CI: 1.79-3.84, P<0.01). Conclusion: High Tiam1 expression was significantly associated with shorter survival and positive lymphatic metastasis in patients with malignant solid tumors. Therefore, Tiam1 may be a promising prognostic biomarker and an effective therapeutic target for malignant solid tumors.
Introduction
Cancer has become a leading cause of death and major public health problem worldwide due to its high incidence and mortality1 Although the methods of diagnosis and treatment of cancers have been greatly improved in recent years, long-term survival in some types of cancers remains unsatisfied as a whole1 Tumor biomarkers have values of early detection, prognosis evaluation and drug discovery of cancers, so as to identify specific biomarkers have been attracting many researchers. 2 A great plenty of tumor biomarkers have been discovered in recent years, but only a handful of biomarkers could be applied for clinical practice.
T-cell lymphoma invasion and metastasis-inducing factor 1 (Tiam1), a specific guanine nucleotide exchange factor, a member of the Rho GTPase family, was first discovered by Habets et al and identified as an invasion and metastasisrelated gene in mice with aggressive T-cell lymphoma. 4, 5 The TIAM1 gene is located in the q22 band of chromosome 21 and the centromeric end of the AML 21 gene and contains 2 exons (~7.3 kb) separated by 1 intron (14 kb) 6 Tiam1 is mainly expressed in normal brain and testis tissues with only minimal or no expressions detected in other normal tissues 7 Additionally, Tiam1 is highly expressed in various cancers as well, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and its overexpression in cancer cells could contribute to proliferation, [24] [25] [26] [27] invasion and metastasis, [28] [29] [30] [31] angiogenesis 32 and chemo-resistance of cancer cells 33 Of note, Tiam1 expressed in tumor stromal microenvironment also plays a role in regulating tumor invasion, metastasis and chemo-resistance. Cancer-associated fibroblast (CAF) is a major stromal cell in cancer stromal microenvironment. 34, 35 A recent study by Izumi et al 33 showed that CAFs isolated from colorectal cancer (CRC) tissues could induce chemoresistance of CRC cells when the two kinds of cells were cocultured, but surprisingly the direct inhibition of Tiam1 in CAFs could result in enhanced chemo-sensitivity of CRC cells 33 Considering the multiple functions of Tiam1 in cancer progression, many researchers focused on exploring the prognostic value of Tiam1. However, the conclusions about the prognostic value of Tiam1 in malignant solid tumors remain controversial. Most of studies suggested that high Tiam1 expression was related to shorter survival in many tumors, including hepatocellular carcinoma, pancreatic cancer, gallbladder cancer, prostate cancer, ovarian cancer and breast cancer. On the contrast, a few of studies indicated that low Tiam1 expression was associated with poor prognosis in patients with gastric cancer 18 and papillary thyroid cancer 12 Considering that most of the single-center studies had the limitations of sample size and methodology, we herein performed a meta-analysis to systematically evaluate the prognostic significance of Tiam1 expression in patients with solid tumor. In addition, Tiam1 is an invasion and metastasis-related gene, so in this meta-analysis, we also performed a pooling analysis to assess the association between Tiam1 expression and lymphatic metastasis.
Materials and methods
This systematic review and meta-analysis were performed according to PRISMA statement issued in 2009 36 Besides, this study was approved by Ethics Committee of Qinghai province people's Hospital.
Literature search strategy
We searched eligible studies in PubMed, Web of Science and EMBASE databases (from inception up to October 2018). The search terms included "cancer," "tumor," "carcinoma," "adenocarcinoma," "neoplasm," "malignant," "malignancy," "Tiam1," "T lymphoma invasion and metastasis 1" "T-cell lymphoma invasion and metastasis inducing factor 1", "survival," "prognosis," and "prognostic." The search strategy used in PubMed was as follows: (((((((((cancer[Title 
Inclusion and exclusion criteria
The inclusion criteria were as follows: 1) the prognostic value of Tiam1 expression in malignant solid tumor in terms of overall survival (OS), recurrence-free survival (RFS) or disease-free survival (DFS) was explored; 2) the Tiam1 expression was divided into high/positive and low/negative groups; 3) HRs and 95% CIs, which were used to estimate the prognostic value of Tiam1 expression, were reported directly or could be calculated from the Kaplan-Meier curves; 4) the studies were published in English; 5) the studies were published in full text and 6) the study was the most informative report, if the same patient population was enrolled into different studies.
The exclusion criteria were as follows: 1) the studies were duplicated publications, reviews, case reports, conference abstracts, editorials or case reports; 2) the studies were only involved in animal and cell experiments and 3) HRs and CIs could not be extracted.
Data extraction and quality assessment
Two independent authors (Caixia Yang and Chenlin Ma) extracted the information from the included literature using a predefined template based on the reporting checklists of PRISMA 36 The following items were extracted:
tumor type, the first author's last name, country, publication year, country, sample number, age, gender, Egger's test 40 were employed to assess the publication bias. Subgroup analysis and meta-regression analysis were performed according to sample size, tumor type, antibody source and quality score to explore the sources of heterogeneity. Sensitivity analysis was conducted by sequentially omitting one study to explore the robustness and reliability of the overall estimated results. All statistical processes were fulfilled using STATA, version 12.0 (Stata Corporation, College Station, TX, USA). All statistical tests were 2-sided, and P p<0.05 was considered as the statistical significance.
Results

Literature selection
The flowchart of literature search and selection is shown in Figure 1 . A total of 161 publications were retrieved from electronic databases. Further, 74 publications were excluded due to duplicates. Then, the remaining publications were reviewed by the title and abstract, in which 66 publications were excluded owing to unrelated topics, nonclinical studies, reviews and conference abstracts. Next, 4 publications were further excluded after full-text reviewing for lacking available data and enrolling overlapped patients. Finally, a total of 17 studies were included in our meta-analysis.
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Basic characteristics of included studies Tables 1 and 2 .
Pooling analysis
A total of 16 studies with 2,168 patients explored the correlation between Tiam1 expression and OS. The random-effects model was employed to pool HRs and their 95% CIs due to the significant heterogeneity among these studies (I 2 =68.2%, p<0.01). The result showed that patients with high Tiam1 expression had shorter OS than those with low expression (HR=2.08, 95% CI: 1.62-2.68, p<0.01; Figure 2 ). Six studies with 845 patients reported the relationship between Tiam1 expression and DFS. Because of no significant heterogeneity (I 2 =48.2%, p=0.08), the fixed effect model was used to pooling data. The result showed that patients with high Tiam1 expression also had shorter OS than those with low expression (HR=1.86, 95% CI: 1.49-2.32, p<0.01; Figure 3 ). Besides, a total of 15 studies with 1,951 patients investigated the relationship between Tiam1 expression and lymph node metastasis. Because of significant heterogeneity (I 2 =61.1%, p<0.01, we pool data on lymphatic metastasis using the random-effect model and found that high Tiam1 expression predicted a higher proportion of lymphatic metastasis (OR=2.63, 95% CI: 1.79-3.84, p<0.05; Figure 4 ).
Subgroup and meta-regression analyses
The subgroup and meta-regression analyses were conducted according to sample size, tumor type, antibody source, definition of high Tiam1 expression and quality score to explore the sources of the heterogeneity in the meta-analyses of the association of Tiam1 expression with OS and lymphatic metastasis. The results of subgroup analysis showed that the significant heterogeneity for OS and lymphatic metastasis still existed in subgroup analysis by any factor (Table 3) . However, the results of meta-regression analysis showed that antibody source might explain the major heterogeneity in the meta-analyses of the association of Tiam1 expression with OS (p<0.01) (Table 4) . Additionally, we found that high Tiam1 expression was associated with shorter OS and positive lymphatic metastasis in all subgroups, only with the exception of subgroup of the other antibody sources, suggesting that our overall estimated results were stable and reliable as a whole.
Sensitivity analysis and publication bias
We conducted sensitivity analysis by sequentially omitting one study to further explore the robustness and reliability of the overall estimated results about OS and lymphatic metastasis. The results showed that our pooled results about OS ( Figure  5A ) and lymphatic metastasis ( Figure 5B ) did not change Notes: Staining index: The product of staining intensity: 0 (negative), 1 (weak), 2 (medium) and 3 (strong) and extent staining score: 1 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%). Multiplied score: the product of staining intensity:0 (negative), 1 (weak), 2 (medium) and 3 (strong) and extent staining score: 1 (0%), 1 (1-25%), 2 (26-50%), 3 (>50%).
Immunoreactive scores: the product of staining intensity: 0 (negative), 1 (weak), 2 (medium) and 3 (strong) and extent staining score 1 (0%), 1 (1-25%), 2 (26-50%), 3 (51-80%) and 4 (>80%). H scores (Histoscore): the product of staining intensity: 0 (negative), 1 (weak), 2 (medium) and 3 (strong) and fraction score (percentage of positive tumor cells; range =0-100). Staining score: the numbers of positively staining cells were scored as 0% (-), 1-33% (+), 34-66% (++) or greater than 67% (+++ significantly when any one of the included studies was omitted, thereby confirming the robustness of the overall estimated results. The Begg's and Egger's tests were conducted to assess the publication bias for OS and lymphatic metastasis. The results showed that the Begg's funnel plots for OS ( Figure 5C ) and lymphatic metastasis ( Figure 5D ) were symmetric, and the p-values of Egger's tests for OS (p=0.804) and lymphatic metastasis (p=0.388) were >0.05, suggesting that there was no significant publication bias. Due to the limited number of eligible studies about DFS, publication bias assessment was not performed in this analysis.
Discussion
Many studies have explored the prognostic value of T-cell lymphoma invasion and metastasis inducing factor 1 (Tiam1) and its association with lymphatic metastasis in malignant solid tumors, but the conclusions remain controversial. Therefore, we performed a meta-analysis to systematically assess the prognostic value of Tiam1 expression and its association with lymphatic metastasis in malignant solid tumors.
To our best knowledge, this study is the first metaanalysis to systematically assess the prognostic value of Tiam1 expression and its association with lymphatic metastasis in patients with malignant solid tumors. A total of 17 studies with 2,228 patients with solid tumors were included in this meta-analysis. The combined results showed that high Tiam1 expression was significantly associated with shorter overall survival (OS; HR = 2.08, 95% CI: 1.62-2.68, P<0.01), and disease-free survival (DFS; HR = 1.86, 95% CI: 1.49-2.32, P<0.01). Besides, we also found that there was a close relationship between high Tiam1 expression and positive lymphatic metastasis (OR=2.63; 95% CI: 1.79-3.84, P<0.01). Furthermore, our subgroup, meta-regression, and sensitivity analyses showed that the overall estimated results were reliable and stable.
Multiple cellular functions of Tiam1 in tumor progression have been elaborated, which may account for the inverse association between Tiam1 expression and survival of cancer patients. First, metastasis is an essential hall marker of cancer and always leads to poor survival. [41] [42] [43] [24] [25] [26] [27] As above, it can be easily deduced that Tiam1 expression in cancer cells is required for facilitating tumor growth, invasion, metastasis and chemo-resistance, which supports the prognostic value of Tiam1. Therefore, Tiam1 in tumor cells may be an attractive therapeutic target. Fourth, increasing evidence showed that the stromal microenvironment within cancers is a pivotal factor of regulating the growth, invasiveness, and metastasis and chemo-sensitivity of cancer cells, [64] [65] [66] [67] [68] and Tiam1 expressed in tumor stromal microenvironment also plays a role in regulating tumor invasion, metastasis and chemo-resistance. CAF is a major stromal cell in cancer stromal microenvironment. 34, 35 Izumi et al 33 found
that CAFs isolated from CRC tissues could induce chemoresistance of CRC cells when the two kinds of cells were cocultured, but surprisingly the direct inhibition of Tiam1 in CAFs could result in enhanced chemo-sensitivity of CRC cells 33 Thus, targeting Tiam1 in tumor stromal may be an ideal way to boost the effectiveness of chemotherapy. However, it was also reported that Tiam1 in tumor-associated fibroblasts had a role in modulating tumor invasion and metastasis, and knockout of Tiam1 in tumor-associated fibroblasts facilitated tumor invasion and metastasis. 69, 70 Therefore, more Ding et al. 2009 A B
C D
Meta-analysis radom-effects estimates (exponential form) study ommited DovePress studies are warranted to fully elucidate the functions of Tiam1 in tumor stromal and to assess the integrated effects of Tiam1 in tumor epithelial cells and stromal. There were some limitations in this meta-analysis. We should cautiously consider when interpreting the results of pooling analysis. First, only studies published in English were included in this meta-analysis, which probably introduced bias. Second, some of the included studies did not directly provide HRs and 95% CIs, and thereby we estimated HRs from the Kaplan-Meier curve using Engage Digitizer 4.1. Inevitably, manually extracting data from Kaplan-Meier curve will cause some calculation errors. Third, there was significant heterogeneity in this meta-analysis. We conducted subgroup and meta-regression analyses based on some factors and identified the antibody source as one of the main sources. In fact, many other factors including age, tumor size, gender, TNM stage, distant metastasis and follow-up time may also cause heterogeneity. However, we failed to conduct subgroup and meta-regression analyses based on these factors due to lacking relevant data in the included studies. Fourth, among all the 17 included studies, only 2 studies with a few patients were from Germany and the rest were all from China, and so it remains unclear whether our findings could be generalized to other populations, especially Caucasian and Africans.
Conclusion
High Tiam1 expression was significantly associated with poor survival and positive lymphatic metastasis in patients with solid tumors. Therefore, Tiam1 may be a promising prognostic biomarker and an effective therapeutic target for solid tumors.
